Terms: = Prostate cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Treatment
116 results:
1. Flubendazole suppresses VEGF-induced angiogenesis in HUVECs and exerts antitumor effects in PC-3 cells.
Zhang B; Zhao J; Kang D; Wang Z; Xu L; Zheng R; Liu A
Chem Biol Drug Des; 2024 Mar; 103(3):e14503. PubMed ID: 38480495
[TBL] [Abstract] [Full Text] [Related]
2. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
3. LncRNA H19 promotes tumor angiogenesis in smokers by targeting anti-angiogenic miRNAs.
Shirvaliloo M
Epigenomics; 2023 Jan; 15(2):61-73. PubMed ID: 36802727
[TBL] [Abstract] [Full Text] [Related]
4. Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in cancer Therapy.
Gales L; Forsea L; Mitrea D; Stefanica I; Stanculescu I; Mitrica R; Georgescu M; Trifanescu O; Anghel R; Serbanescu L
Medicina (Kaunas); 2022 Sep; 58(9):. PubMed ID: 36143915
[TBL] [Abstract] [Full Text] [Related]
5. Radiotherapy alters expression of molecular targets in prostate cancer in a fractionation- and time-dependent manner.
Eke I; Aryankalayil MJ; Bylicky MA; Makinde AY; Liotta L; Calvert V; Petricoin EF; Graves EE; Coleman CN
Sci Rep; 2022 Mar; 12(1):3500. PubMed ID: 35241721
[TBL] [Abstract] [Full Text] [Related]
6. Reversing pathology in a preclinical model of Alzheimer's disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics.
Singh CSB; Choi KB; Munro L; Wang HY; Pfeifer CG; Jefferies WA
EBioMedicine; 2021 Sep; 71():103503. PubMed ID: 34534764
[TBL] [Abstract] [Full Text] [Related]
7. Ultrasound Molecular Imaging for the Guidance of Ultrasound-Triggered Release of Liposomal Doxorubicin and Its treatment Monitoring in an Orthotopic Prostatic Tumor Model in Rat.
Helbert A; von Wronski M; Mestas JL; Tardy I; Bettinger T; Lafon C; Hyvelin JM; Padilla F
Ultrasound Med Biol; 2021 Dec; 47(12):3420-3434. PubMed ID: 34503895
[TBL] [Abstract] [Full Text] [Related]
8. [Pharmacological properties and clinical outcomes of the anti-cancer drug, cabozantinib (CABOMETYX
Osaka T; Yamaguchi N; Hara T
Nihon Yakurigaku Zasshi; 2021; 156(5):303-311. PubMed ID: 34470936
[TBL] [Abstract] [Full Text] [Related]
9. Protein kinase inhibitors for the treatment of prostate cancer.
Chau V; Madan RA; Aragon-Ching JB
Expert Opin Pharmacother; 2021 Oct; 22(14):1889-1899. PubMed ID: 33989112
[TBL] [Abstract] [Full Text] [Related]
10. Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature.
Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Lin DW; Corey E; Nelson PS; Morrissey C
PLoS One; 2021; 16(1):e0245602. PubMed ID: 33471819
[TBL] [Abstract] [Full Text] [Related]
11. Design, synthesis and evaluation of novel thienopyrimidine-based agents bearing diaryl urea functionality as potential inhibitors of angiogenesis.
Faraji A; Oghabi Bakhshaiesh T; Hasanvand Z; Motahari R; Nazeri E; Boshagh MA; Firoozpour L; Mehrabi H; Khalaj A; Esmaeili R; Foroumadi A
Eur J Med Chem; 2021 Jan; 209():112942. PubMed ID: 33328104
[TBL] [Abstract] [Full Text] [Related]
12. Efficacy and Effect of Cabozantinib on Bone Metastases in treatment-naive Castration-resistant prostate cancer.
Smith DC; Daignault-Newton S; Grivas P; Reichert ZR; Hussain M; Cooney KA; Caram M; Alva A; Jacobson J; Yablon C; Mehra R; Escara-Wilke J; Shelley G; Keller ET
Clin Genitourin Cancer; 2020 Aug; 18(4):332-339.e2. PubMed ID: 32299729
[TBL] [Abstract] [Full Text] [Related]
13. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic prostate cancer.
Corn PG; Zhang M; Nogueras-Gonzalez GM; Xiao L; Zurita AJ; Subudhi SK; Tu SM; Aparicio AM; Coarfa C; Rajapakshe K; Huang S; Navone NM; Lin SH; Wang G; Ramachandran S; Titus MA; Panaretakis T; Gallick GE; Efstathiou E; Troncoso P; Logothetis C
Clin Cancer Res; 2020 Mar; 26(5):990-999. PubMed ID: 31941830
[TBL] [Abstract] [Full Text] [Related]
14. Discovering Therapeutic Protein Targets for Bladder cancer Using Proteomic Data Analysis.
Bahrami S; Kazemi B; Zali H; Black PC; Basiri A; Bandehpour M; Hedayati M; Sahebkar A
Curr Mol Pharmacol; 2020; 13(2):150-172. PubMed ID: 31622214
[TBL] [Abstract] [Full Text] [Related]
15. Novel human Ab against vascular endothelial growth factor receptor 2 shows therapeutic potential for leukemia and prostate cancer.
Lu RM; Chiu CY; Liu IJ; Chang YL; Liu YJ; Wu HC
Cancer Sci; 2019 Dec; 110(12):3773-3787. PubMed ID: 31578782
[TBL] [Abstract] [Full Text] [Related]
16. Antiangiogenic therapy with Nintedanib affects hypoxia, angiogenesis and apoptosis in the ventral prostate of TRAMP animals.
da Silva RF; Banzato TP; Alves LF; Carvalho JE; Agarwal R; Cagnon VHA
Cell Tissue Res; 2020 Feb; 379(2):407-420. PubMed ID: 31473819
[TBL] [Abstract] [Full Text] [Related]
17. 6-sialyllactose ameliorates dihydrotestosterone-induced benign prostatic hyperplasia through suppressing VEGF-mediated angiogenesis.
Kim EY; Jin BR; Chung TW; Bae SJ; Park H; Ryu D; Jin L; An HJ; Ha KT
BMB Rep; 2019 Sep; 52(9):560-565. PubMed ID: 31383249
[TBL] [Abstract] [Full Text] [Related]
18. Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models.
Luo Y; Azad AK; Karanika S; Basourakos SP; Zuo X; Wang J; Yang L; Yang G; Korentzelos D; Yin J; Park S; Zhang P; Campbell JJ; Schall TJ; Cao G; Li L; Thompson TC
Int J Cancer; 2018 May; 142(10):2163-2174. PubMed ID: 29277895
[TBL] [Abstract] [Full Text] [Related]
19. Expression of phosphatase of regenerating liver (PRL)-3, is independently associated with biochemical failure, clinical failure and death in prostate cancer.
Andersen S; Richardsen E; Rakaee M; Bertilsson H; Bremnes R; Børset M; Busund LT; Slørdahl T
PLoS One; 2017; 12(11):e0189000. PubMed ID: 29190795
[TBL] [Abstract] [Full Text] [Related]
20. Discovery of Novel Potent vegfr-2 Inhibitors Exerting Significant Antiproliferative Activity against cancer Cell Lines.
Zhang Y; Chen Y; Zhang D; Wang L; Lu T; Jiao Y
J Med Chem; 2018 Jan; 61(1):140-157. PubMed ID: 29189002
[TBL] [Abstract] [Full Text] [Related]
[Next]
